Brian I Carr1, Ziqiu Wang, Meifung Wang, Gang Wei. 1. Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. brianicarr@hotmail.com
Abstract
PURPOSE: DCP is a useful HCC tumor marker, which reflects a defect in vitamin K metabolism. We tested the hypothesis that vitamin K treatment of HCC patients might suppress this marker and possibly AFP also. EXPERIMENTAL DESIGN:HCC patients who had both elevated AFP and DCP were included. A phase I cohort was treated with escalating vitamin K1 intravenous weekly doses and a 27-patient phase II cohort was then treated with a fixed oral daily dose. RESULTS: A maximum tolerated dose was not reached up to 100-fold the normal vitamin K1 dose. No toxicities were found up to 1,000 mg/infusion. In the phase II cohort, 93% of patients had tumor marker responses by decreased DCP levels, but only 22% had responses by decreased AFP levels. CT scans showed 11% of patients had PRs, 59% had stable tumors and 29.6% had tumor progression. Mechanism studies showed that vitamin K1 induced phosphorylation of JNK and c-Jun and caspase-mediated apoptosis. CONCLUSIONS:Vitamin K1 was non-toxic at high doses, strongly inhibited plasma DCP levels, but weakly suppressed AFP levels. The results provide evidence that the two tumor markers are not directly linked and that DCP levels may not reflect HCC cell growth, as DCP levels were decreased in patients without AFP change, and were suppressed in vitro at 1% of the vitamin K1 concentration needed to inhibit AFP.
RCT Entities:
PURPOSE: DCP is a useful HCC tumor marker, which reflects a defect in vitamin K metabolism. We tested the hypothesis that vitamin K treatment of HCC patients might suppress this marker and possibly AFP also. EXPERIMENTAL DESIGN: HCC patients who had both elevated AFP and DCP were included. A phase I cohort was treated with escalating vitamin K1 intravenous weekly doses and a 27-patient phase II cohort was then treated with a fixed oral daily dose. RESULTS: A maximum tolerated dose was not reached up to 100-fold the normal vitamin K1 dose. No toxicities were found up to 1,000 mg/infusion. In the phase II cohort, 93% of patients had tumor marker responses by decreased DCP levels, but only 22% had responses by decreased AFP levels. CT scans showed 11% of patients had PRs, 59% had stable tumors and 29.6% had tumor progression. Mechanism studies showed that vitamin K1 induced phosphorylation of JNK and c-Jun and caspase-mediated apoptosis. CONCLUSIONS:Vitamin K1 was non-toxic at high doses, strongly inhibited plasma DCP levels, but weakly suppressed AFP levels. The results provide evidence that the two tumor markers are not directly linked and that DCP levels may not reflect HCC cell growth, as DCP levels were decreased in patients without AFP change, and were suppressed in vitro at 1% of the vitamin K1 concentration needed to inhibit AFP.
Authors: Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; H Yoshida; S Shiina; M Omata Journal: Cancer Date: 2001-02-01 Impact factor: 6.860
Authors: Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz Journal: Gastroenterology Date: 2009-04-09 Impact factor: 22.682
Authors: Vladimir Bespalov; Alexander Sherbakov; Viktor Novik; Valentin Kalinovsky; Kamran Shamsi; Vagif Soultanov Journal: Evid Based Complement Alternat Med Date: 2016-11-28 Impact factor: 2.629
Authors: Quirino Lai; Fabio Melandro; Rafael S Pinheiro; Andrea Donfrancesco; Bashir A Fadel; Giovanni B Levi Sandri; Massimo Rossi; Pasquale B Berloco; Fabrizio M Frattaroli Journal: Int J Hepatol Date: 2012-06-27
Authors: Hikmet Akkiz; Brian I Carr; Sedef Kuran; Ümit Karaoğullarından; Oguz Üsküdar; Salih Tokmak; Burcu Arslan; Figen Doran; Hüseyin Tugsan Balli; Abdulalh Ülkü; Tolga Atılgan Akçam; Halil İbrahim Bahçeci; Kamil Yalçın Polat; Necati Örmeci; Halis Şimşek; Abdullah Sonsuz; Ali Demir; Engin Altıntaş; Mehmet Demir; Kendal Yalçın; Nazım Ekinci; Ayşegül Harmancı Özakyol; Mehmet Yücesoy; Ahmet Uygun; Vito Guerra; Anıl Delik; Yaman Tokat; Sezai Yilmaz; Ahmet Bektaş; Murat Kılıç Journal: Can J Gastroenterol Hepatol Date: 2018-06-13